Shopping Cart 0
Cart Subtotal
USD 0

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Immatics Biotechnologies GmbH-Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-GlobalData's summarization of the company's business strategy.

- SWOT analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

Highlights

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Jan 11,2019: Immatics at the 18th PepTalk in San Diego, CA

Jan 03,2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company's Leading Role in the Field of Innovative Immunotherapies

Sep 28,2018: Immatics at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Sept 30-Oct 3) in New York, NY

Aug 31,2018: Immatics to present at the Cell & Gene Therapy Bioprocessing & Commercialization 2018

Aug 31,2018: Immatics to present at the CAR-TCR Summit 2018 (Sept 4-7)

Reasons to buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

- Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

- Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Immatics Biotechnologies GmbH-Key Facts

Immatics Biotechnologies GmbH-Key Employees

Immatics Biotechnologies GmbH-Key Employee Biographies

Immatics Biotechnologies GmbH-Major Products and Services

Immatics Biotechnologies GmbH-History

Immatics Biotechnologies GmbH-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Immatics Biotechnologies GmbH-Business Description

Immatics Biotechnologies GmbH-SWOT Analysis

SWOT Analysis-Overview

Immatics Biotechnologies GmbH-Strengths

Immatics Biotechnologies GmbH-Weaknesses

Immatics Biotechnologies GmbH-Opportunities

Immatics Biotechnologies GmbH-Threats

Immatics Biotechnologies GmbH-Key Competitors

Section 3-Company's Lifesciences Financial Deals and Alliances

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Immatics Biotechnologies GmbH, Recent Deals Summary

Section 4-Company's Recent Developments

Jan 11, 2019: Immatics at the 18th PepTalk in San Diego, CA

Jan 03, 2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company's Leading Role in the Field of Innovative Immunotherapies

Sep 28, 2018: Immatics at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Sept 30-Oct 3) in New York, NY

Aug 31, 2018: Immatics to present at the Cell & Gene Therapy Bioprocessing & Commercialization 2018

Aug 31, 2018: Immatics to present at the CAR-TCR Summit 2018 (Sept 4-7)

Jul 16, 2018: Genmab and Immatics to develop bispecific cancer therapies

May 14, 2018: Immatics Appoints Stephen Eck as Chief Medical Officer US

Jan 17, 2018: Immatics Appoints Thomas Ulmer as CFO

Section 5-Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Immatics Biotechnologies GmbH, Key Facts

Immatics Biotechnologies GmbH, Key Employees

Immatics Biotechnologies GmbH, Key Employee Biographies

Immatics Biotechnologies GmbH, Major Products and Services

Immatics Biotechnologies GmbH, History

Immatics Biotechnologies GmbH, Other Locations

Immatics Biotechnologies GmbH, Subsidiaries

Immatics Biotechnologies GmbH, Key Competitors

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Immatics Biotechnologies GmbH, Recent Deals Summary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Immatics Biotechnologies GmbH, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Overview, Key Manufacturing Facilities, Key Information, Overview, Business Description, Major Products and Services, Brands, History, Key Employees, Key Employee Biographies, Key Operational Heads, Locations And Subsidiaries, Competitors, Company Statement.


Companies

Lindis Biotech GmbH

ProQinase GmbH

Affimed GmbH

Immunocore Ltd

Intezyne Inc

Pieris AG